- Home
- DHY vs TLSI Comparison
DHY vs TLSI Comparison
Compare DHY & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- TLSI
- Stock Information
- Founded
- DHY 1998
- TLSI 2010
- Country
- DHY United States
- TLSI United States
- Employees
- DHY N/A
- TLSI N/A
- Industry
- DHY Finance/Investors Services
- TLSI Medical Specialities
- Sector
- DHY Finance
- TLSI Health Care
- Exchange
- DHY Nasdaq
- TLSI Nasdaq
- Market Cap
- DHY 211.3M
- TLSI 204.0M
- IPO Year
- DHY N/A
- TLSI N/A
- Fundamental
- Price
- DHY $2.12
- TLSI $4.56
- Analyst Decision
- DHY
- TLSI Strong Buy
- Analyst Count
- DHY 0
- TLSI 5
- Target Price
- DHY N/A
- TLSI $10.90
- AVG Volume (30 Days)
- DHY 569.1K
- TLSI 134.8K
- Earning Date
- DHY 01-01-0001
- TLSI 08-13-2025
- Dividend Yield
- DHY 9.10%
- TLSI N/A
- EPS Growth
- DHY N/A
- TLSI N/A
- EPS
- DHY N/A
- TLSI N/A
- Revenue
- DHY N/A
- TLSI $32,141,000.00
- Revenue This Year
- DHY N/A
- TLSI $55.39
- Revenue Next Year
- DHY N/A
- TLSI $54.89
- P/E Ratio
- DHY N/A
- TLSI N/A
- Revenue Growth
- DHY N/A
- TLSI 46.20
- 52 Week Low
- DHY $1.77
- TLSI $3.50
- 52 Week High
- DHY $2.08
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- DHY 49.44
- TLSI 39.21
- Support Level
- DHY $2.10
- TLSI $4.41
- Resistance Level
- DHY $2.00
- TLSI $4.73
- Average True Range (ATR)
- DHY 0.02
- TLSI 0.22
- MACD
- DHY -0.00
- TLSI -0.02
- Stochastic Oscillator
- DHY 30.00
- TLSI 18.99
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.